Nabota 150U Botulinum Toxin Type A

Nabota 150U, manufactured by Daewoong Pharmaceutical in South Korea, is a highly purified botulinum toxin type A formulation developed using an advanced manufacturing and purification process. It is designed to provide consistent potency, reliable performance, and predictable aesthetic outcomes when administered by qualified medical professionals.

Nabota is recognized for its 99.99% high-purity botulinum toxin type A complex and stringent manufacturing standards. Its purification process is designed to minimize unnecessary impurities and deliver a highly consistent finished product.

High Purity & Consistent Performance

The purity and manufacturing quality of botulinum toxin products are important considerations for both treatment consistency and long-term use.

Nabota’s highly purified formulation is designed to provide:

• Consistent and predictable performance
• Reliable aesthetic results
• High product purity
• Precise botulinum toxin activity
• Quality-controlled manufacturing in South Korea

Low Immunogenicity Potential

Repeated exposure to botulinum toxin may, in some patients, contribute to the development of neutralizing antibodies, which can potentially reduce treatment responsiveness over time.

Nabota’s highly purified formulation and controlled manufacturing process are designed to minimize unnecessary protein impurities and support a low immunogenicity profile.

For patients experiencing reduced responsiveness to previous botulinum toxin treatments, the underlying cause should be evaluated by a qualified healthcare professional. Treatment response can be affected by multiple factors, including dosage, injection technique, treatment interval, muscle anatomy, product handling, and true antibody-mediated resistance.

Key Benefits

• 150 Units per vial
• Botulinum toxin type A
• Manufactured by Daewoong Pharmaceutical, South Korea
• Advanced purification and manufacturing technology
• High-purity formulation
• Designed for consistent and reliable performance
• Low immunogenicity profile
• Professional medical use only

FDA Approval Information

Daewoong’s botulinum toxin type A formulation is marketed in the United States as Jeuveau® (prabotulinumtoxinA-xvfs), which received U.S. FDA approval for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.